供应商 · 生产商 · 农业生物技术与农业科技

Qianjiang Biochemical 钱江生化 (SSE 600796)

浙江钱江生物化学股份有限公司是一家生物技术公司,总部位于中国浙江嘉兴。

运营中中国亚洲成立 1970 核实于 2026-10-05

简介

Zhejiang Qianjiang Biochemical (SSE 600796) is a China-based company headquartered in Haining, Zhejiang, founded in 1970. It operates two primary business segments: water and environmental protection (its largest revenue source) and biological manufacturing.

The company produces biopesticides, including gibberellic acid (global production leader), jinggangmycin (over 50% domestic market share), and avermectin series products. It is actively pivoting toward synthetic biology to optimize production strains and reduce costs.

Listed on the Shanghai Stock Exchange, the company reported 2025 revenue of 1.69 billion CNY. It remains active in 2026, focusing on its 1225 strategy to integrate green industry upgrades.

Sources#

行业: 生物炼制, 植物保护, 工业化学
主题: 生物农药与生物防治, 合成生物学平台与生物制造, 有机酸与生物基化学品, 植保化学品与肥料
角色: 生产商 — “…enue source) and biological manufacturing [2][3]. The company produces biopesticides, including gibberellic ac…”

供应的生物解决方案 0

尚未被列为已评级方案的供应商。

产品与服务

该公司未公开其产品或服务——我们可通过引荐了解。

新闻与状态 6

2026-08 最新状态: 董事长、总经理朱燕刚因工作调动离任,邵海军当选新任董事长。 ↗ ↗ ↗
2026-09-29 浙江钱江生物化学股份有限公司关于持股5%以上股东所持部分公司股份将被司法拍卖的提示性公告|上海证券报
浙江钱江生物化学股份有限公司公告称，其持股5%以上股东云南水务投资股份有限公司所持8,012,511股公司股份将被司法拍卖，该股份为限售流通股，占公司总股本约0.92%。拍卖由广东省揭阳市法院在淘宝司法拍卖平台进行，拍卖时间为2026年11月5日至11月6日，拍卖结果不影响公司实际控制权、生产经营或治理。
2026-08-26 钱江生化上半年扣非净利润增长36.77% 提质增效成果显著_新浪财经_新浪网
Qianjiang Biochemical (钱江生化) reports a 36.77% year-on-year rise in non-net profit (扣非净利润) for H1 2026, driven by reduced losses in waste treatment, higher investment income from its stake in Guangyao Thermal Power, improved gross margin to 27.86%, and …
2026-08-26 钱江生化2026年半年报：扣非净利增三成，营收利润双降
Qianjiang Biochemical (钱江生化)2026H1 shows revenue and net profit both declined due to weaker agrochemical demand and lower waste treatment prices, but non-recurring items boosted扣非净利润, signaling improved core profitability. The water-environment protection …
2026-09-23 浙江嘉兴市银建工程咨询评估有限公司关于浙江钱江生物化学股份有限公司2026~2027年度大宗生产性药剂药品采购项目—PAM(污水)中标(成交)结果公告 - 污水处理服务中标
Summary: The announcement states that Zhejiang Jiashang (Qianjiang) Biochemical Co., Ltd. has awarded a contract for the 2026–2027 bulk production-related pharmaceutical reagent procurement project—specifically PAM for wastewater treatment—with the bid/result …
2026-09-07 钱江生化：9月2日召开业绩说明会，投资者参与
Qianjiang Biochemical (钱江生化)披露2026年上半年业绩：营收7.33亿元，同比下降5.95%；归母净利润0.779亿元，同比下降27.4%，但扣非净利润同比增长36.77%；公司正推进低效资产处置、降本控费和光伏扩容等节能增效举措，并计划以“六张网”提升基础设施与清洁能源布局。
2026-04-03 Zhejiang Qianjiang Biochemical's chairman resigns | MarketScreener
The article reports that Zhejiang Qianjiang Biochemical’s chairman has resigned. It provides a brief market snapshot and situates the news in the company’s ongoing listed-status covered by Reuters on March 4, 2026.

关系网络：股东、合作伙伴、同类

身份与联系方式

联系方式、人员和法律信息仅向会员开放。

会员登录